CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

All Therapeutic Areas
🛡️

Immunology & Inflammation

107 drugs in pipeline from 10 companies

107

Drugs in Pipeline

10

Companies

10

Upcoming Catalysts

107

Phase 3 Trials

Upcoming Catalysts
6d
NVSEFPhase 3

Ianalumab Phase 3 Results Expected

Ianalumab226
Apr 24
CT.gov
00%
2w
RHHBYPhase 3

Rituximab Phase 3 Results Expected

Rituximab1,000
Apr 30
CT.gov
00%
2w
AZNCFPhase 2

Tozorakimab Phase 2 Results Expected

Tozorakimab98
Apr 30
CT.gov
00%
2w
TLSAPhase 2

Foralumab TZLS-401 100 µg Phase 2 Results Expected

Foralumab TZLS-401 100 µg55
Apr 30
CT.gov
00%
2w
NVSPhase 3

Remibrutinib Phase 3 Results Expected

Remibrutinib1,011
Apr 30
CT.gov
00%
2w
AZNCFPhase 2

AZD7798 Phase 2 Results Expected

AZD7798120
May 1
CT.gov
00%
3w
AZNPhase 2

AZD7798 Phase 2 Results Expected

AZD779830
May 4
CT.gov
00%
3w
TAKPhase 3
Positive

TAK-279 Phase 3 Results Expected

TAK-2791,950
May 7
CT.gov
4w
REGNPhase 2

Placebo Phase 2 Results Expected

Dupilumab180
May 13
CT.gov
00%
4w
ABBVPhase 3
Positive

Risankizumab IV Phase 3 Results Expected

risankizumab IV1,336
May 15
CT.gov
Pipeline by Phase
Phase 3
107
Related Conditions
autoimmunerheumatoid arthritislupuspsoriasiscrohnulcerative colitisibdinflammatoryimmuneimmunologyeczemadermatitisankylosing spondylitismultiple sclerosisgrafttransplantrejectionallergyasthma